Plain-English translation of NCT07315087 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing whether , a new type of engineered immune cell therapy, can safely treat autoimmune diseases that have stopped responding to standard medicines. The treatment involves giving you a single infusion of specially designed immune cells that target parts of your immune system that are causing disease. Researchers will watch carefully to see how safe the treatment is and whether it helps control your disease over the first 6 months.
People with severe autoimmune diseases like lupus, scleroderma, and vasculitis sometimes stop responding to all available standard treatments, leaving them with few options. This medication represents a completely new approach—using engineered immune cells to calm down the overactive immune system rather than just suppressing it with traditional drugs.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first receive a short course of chemotherapy to prepare your body, then receive a single infusion of the engineered immune cells through an IV. After that, you will have follow-up visits at 12 weeks and 24 weeks to check your safety and how well the treatment is working. You may need additional visits beyond that, and the research team will monitor your blood counts, organ function, and disease activity throughout the study.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Shanghai Xiniao Biotech Co., Ltd.
Enrollment target
~12 participants
Started
January 2026
Primary completion
January 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ying Wang, MD
Institute of Hematology & Blood Diseases Hospital, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.